Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Maze Therapeutics in a research note issued to investors on Monday, March 31st. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.64) per share for the quarter, down from their previous estimate of ($0.58). Leerink Partnrs has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics' Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($2.78) EPS and FY2027 earnings at ($2.55) EPS.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($18.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.60) by ($10.72).
MAZE has been the subject of a number of other reports. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. Leerink Partners started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price objective on the stock. Guggenheim reissued a "buy" rating and set a $19.00 price target on shares of Maze Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. started coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an "overweight" rating and a $30.00 price target for the company. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Maze Therapeutics has an average rating of "Buy" and an average target price of $25.67.
Check Out Our Latest Report on MAZE
Maze Therapeutics Trading Down 2.7 %
MAZE traded down $0.25 during midday trading on Thursday, reaching $9.07. The company had a trading volume of 327,522 shares, compared to its average volume of 303,896. Maze Therapeutics has a 12-month low of $8.33 and a 12-month high of $17.00.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Recommended Stories
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
